Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

A/Prof Spiros Fourlanos & Samantha Stuk

Maintaining Muscle Mass & Nutritional Status While Losing Weight on GLP-1RAs

A/Prof Ralph Audehm & A/Prof Jeremy Grummet

Prostate Cancer Screening Recommendations – Case Discussion & Q&A

Dr Alison Chiu

Dry Eye – Practical Management Tips for Better Outcome

Dr Ted Wu

Cardiovascular Outcomes & GLP1 – An Update

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

30 September 2025

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD